Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral

It discussed the following issues (issues 1, 2 and 3), which were outstanding after the technical engagement stage. Clinical need and current management Patients rely on clinicians to discuss with them the benefits and risks of treatment options 3.1 The patient expert explained that people with coronary or peripheral artery disease have serious concerns about the risk of having events such as heart attack and stroke. They noted that coronary or peripheral artery disease is a challenging condition requiring significant lifestyle adjustments, including diet and exercise, which can affect the whole family. It is important that people understand why they are being offered a dual therapy and how the drugs work, because this can help with adherence to treatment. The patient expert explained that patients rely on clinicians to discuss with them the best treatment options. All options should be discussed, weighing up the potential benefits and risks of potentially long-term medication. The committee concluded that patients rely on clinicians to present the best treatment options to them, and all potential benefits and risks should be fully discussed. Patients would welcome an additional treatment option with an acceptable benefit-risk ratio for the prevention of atherothrombotic events 3.2 NICE's guideline on
